Charles E. Geyer, MD, FACP

  • 31526 Citations
  • 58 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

Charles E. Geyer, Jr., is Deputy Director of the Houston Methodist Cancer Center and has devoted most of his academic career on the design and conduct of multi-institutional, phase III clinical trials in breast cancer with a focus on the development of HER2 targeted therapies.  He has served in several leadership positions for the National Surgical Adjuvant Breast and Bowel Project (NSABP) which include vice-chair of the Breast Committee from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011. In 2008, he was appointed as a founding Co-chair for the NCI Cancer Treatment Evaluation Program Breast Cancer Steering Committee and received a Director’s Award at the completion of his tenure in 2011. 

He earned his bachelor’s and doctoral degrees from Texas Tech University in Lubbock, Texas and completed his internal medicine residency and medical oncology fellowship at Baylor College of Medicine Affiliated Hospitals in Houston, Texas.

Research interests

Currently he serves as vice chair of the NRG Breast Committee and chair of the NSABP Foundation Breast Cancer Committee.  Dr. Geyer served as study PI on the KATHERINE trial and study co-chair for the OlympiA trial, a global phase III study of olaparib as adjuvant therapy for patients with germline BRCA mutations and high risk early breast cancer.  He is also PI for NRG BR004, a trial evaluating atezolizumab in first-line therapy of HER2 positive metastatic breast cancer, and co-PI for NSABP B-59/GEPARDOUZE evaluating atezolizumab as neoadjuvant and adjuvant therapy in combination with chemotherapy for early stage TNBC.  Dr. Geyer has co-authored over 80 peer-reviewed manuscripts including results of several landmark phase 3 trials conducted by the NSABP. 

Education/Academic qualification

Medical Oncology, Clinical Fellowship, Baylor College of Medicine

Mar 1 1984Feb 1 1986

Award Date: Feb 1 1986

Internal Medicine, Residency, Baylor College of Medicine

Jun 1 1980Jun 1 1983

Award Date: Jun 1 1983

MD, Texas Tech University Health Sciences Center School of Medicine

Aug 1 1976Jun 1 1980

Award Date: Jun 1 1980

Research Area Keywords

  • Cancer
  • Clinical Translation & Trials
  • Clinical Care

Free-text keywords

  • HER2 positive breast cancer
  • Clinical trials in early breast cancer
  • Immunotherapy

Fingerprint Dive into the research topics where Charles E. Geyer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

Breast Conservation after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results from the BrighTNess Randomized Clinical Trial

Golshan, M., Loibl, S., Wong, S. M., Houber, J. B., O'Shaughnessy, J., Rugo, H. S., Wolmark, N., McKee, M. D., Maag, D., Sullivan, D. M., Metzger-Filho, O., Von Minckwitz, G., Geyer, C. E., Sikov, W. M. & Untch, M., Mar 2020, In : JAMA Surgery. 155, 3, e195410.

Research output: Contribution to journalArticle

  • 7 Scopus citations

    Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

    Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., Hayes, D. F. & 9 others, Dees, E. C., Geyer, C., Olson, J. A., Wood, W. C., Lively, T., Paik, S., Ellis, M. J., Abrams, J. & Sledge, G. W., Mar 2020, In : JAMA oncology. 6, 3, p. 367-374 8 p.

    Research output: Contribution to journalArticle

  • 18 Scopus citations

    Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial

    Golshan, M., Wong, S. M., Loibl, S., Huober, J. B., O'Shaughnessy, J., Rugo, H. S., Wolmark, N., Ansell, P., Maag, D., Sullivan, D. M., Metzger-Filho, O., Von Minckwitz, G., Geyer, C. E., Sikov, W. M. & Untch, M., Feb 2020, In : European Journal of Surgical Oncology. 46, 2, p. 223-228 6 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response

    Swain, S. M., Tang, G., Brauer, H. A., Goerlitz, D. S., Lucas, P. C., Robidoux, A., Harris, B. T., Bandos, H., Ren, Y., Geyer, C. E., Rastogi, P., Mamounas, E. P. & Wolmark, N., Aug 15 2020, In : Clinical cancer research : an official journal of the American Association for Cancer Research. 26, 16, p. 4233-4241 9 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+

    Fehrenbacher, L., Cecchini, R. S., Geyer, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J. F., Provencher, L., Stokoe, C., Moore, T. D., Robidoux, A., Flynn, P. J., Borges, V. F., Albain, K. S., Swain, S. M., Paik, S., Mamounas, E. P. & Wolmark, N., Feb 10 2020, In : Journal of Clinical Oncology. 38, 5, p. 444-453 10 p.

    Research output: Contribution to journalArticle

  • 8 Scopus citations